| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.41▲ | 2.46▼ | 2.48▼ | 2.43▲ | 2.77▼ |
| MA10 | 2.41▲ | 2.50▼ | 2.48▼ | 2.50▼ | 3.07▼ |
| MA20 | 2.44▼ | 2.50▼ | 2.47▼ | 2.78▼ | 3.55▼ |
| MA50 | 2.50▼ | 2.42▲ | 2.51▼ | 3.18▼ | N/A |
| MA100 | 2.50▼ | 2.51▼ | 2.61▼ | N/A | N/A |
| MA200 | 2.46▼ | 2.63▼ | 2.94▼ | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.001▼ | -0.015▼ | -0.002▼ | -0.013▼ | N/A |
| RSI | 42.066▼ | 42.908▼ | 45.115▼ | 36.153▼ | 30.592▼ |
| STOCH | 28.358 | 33.052 | 48.936 | 34.077 | 10.281▼ |
| WILL %R | -60.000 | -79.412▼ | -88.333▼ | -68.269 | -89.320▼ |
| CCI | -36.903 | -136.429▼ | -152.769▼ | -80.622 | -153.121▼ |
|
Thursday, April 02, 2026 04:19 AM
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
|
|
Wednesday, March 18, 2026 05:11 PM
The following slide deck was published by NovaBridge Biosciences in conjunction with this event.
|
|
Monday, March 09, 2026 03:23 AM
The Phase 2a study results revealed that VIS-101 produced rapid and durable treatment responses with both 3 mg and 6 mg dose cohorts in patients with wet age-related macular degeneration (wet AMD).
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 02/04/26 | 2.38 | 2.57 | 2.372 | 2.43 | 1,523,619 |
| 01/04/26 | 2.52 | 2.70 | 2.46 | 2.46 | 1,968,412 |
| 31/03/26 | 2.27 | 2.46 | 2.23 | 2.46 | 1,021,137 |
| 30/03/26 | 2.55 | 2.578 | 2.10 | 2.24 | 2,550,897 |
| 27/03/26 | 2.58 | 2.73 | 2.535 | 2.54 | 471,489 |
| 26/03/26 | 2.545 | 2.695 | 2.53 | 2.55 | 449,691 |
| 25/03/26 | 2.53 | 2.77 | 2.52 | 2.64 | 886,723 |
| 24/03/26 | 2.61 | 2.61 | 2.44 | 2.52 | 1,147,318 |
| 23/03/26 | 2.60 | 2.65 | 2.5414 | 2.63 | 301,537 |
| 20/03/26 | 2.75 | 2.76 | 2.53 | 2.56 | 489,007 |
|
|
||||
|
|
||||
|
|